- All News
- In the News
- Press Releases
FDA Clears SeptiCyte® RAPID – The First One-Hour, Direct-from-Blood Sepsis Test
Fully automated diagnostic tool SeptiCyte® RAPID quantifies the relative expression levels of genes involved in a patient's immune response to infection to aid in a diagnosis in one hour for patients suspected of sepsis Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced...
Superior Sepsis Diagnostic Performance of SeptiCyte® RAPID Compared to Lactate and Procalcitonin Presented at IDWeek 2021
SeptiCyte® RAPID proved superior to routinely used diagnostic tools for the differentiation of sepsis from infection negative systemic inflammation SEATTLE, Sept. 29, 2021 /PRNewswire/ -- Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced a presentation, titled "Comparison of lactate, procalcitonin and a gene signature assay...
Comparison of Lactate, Procalcitonin and a Gene Signature Assay Alone or in Combination to Differentiate Sepsis from Infection Negative Systemic Inflammation in ICU Patients
Immunexpress to Present SeptiCyte® RAPID Comparative Data Against Lactate and Procalcitonin for Diagnosing Sepsis at IDWeek 2021
Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced a presentation demonstrating comparative data of SeptiCyte® RAPID, lactate, and procalcitonin in differentiating sepsis from infection negative systemic inflammation at IDWeek 2021, taking place virtually on Sept. 29 – Oct. 3, 2021. Details...
SeptiCyte RAPID is highlighted in this 10News First Brisbane interview. The country's largest pediatric sepsis study at the Queensland Children's Hospital is working on finding simple diagnostic blood tests for the 5,000 Australians a year and robs others of their limbs.
Immunexpress Announces SeptiCyte® RAPID Testing For Paediatric Sepsis
BRISBANE, Australia, Aug. 24, 2021 /PRNewswire/ -- Immunexpress, Pty Ltd, a molecular diagnostic company founded in Brisbane, today announced that the SeptiCyte® RAPID test will be evaluated in the diagnosis of paediatric sepsis in Queensland children. The testing is in part funded through a Federal Government's Medical Research Future Fund Genomic Health Futures Mission grant for...
Immunexpress Presents Data Supporting SeptiCyte® RAPID for COVID-19 Patient Triage as a Late-Breaking Abstract at ECCMID 2021
SEATTLE, July 9, 2021 – Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced a late-breaking presentation, titled “Use of SeptiCyte RAPID to assess the risk of ICU admission in COVID-19 patients” (ID#4984), demonstrating the performance of SeptiCyte® RAPID in triaging COVID-19 patients...
Use of SeptiCyte® RAPID Assay to Assess the Risk of ICU admission in COVID-19 Patients
Finding The Product- Market Fit, with Rollie Carlson Ph.D. CEO of Immunexpress
Gurus, why should you have your engineers and researchers out in the field? How can they get a good product-market fit? What is the NOT INVENTED HERE factor and why should you avoid it? Dr. Carlson discusses this and more. Listen in as he provides further evidence that perfect should...
The Role of a Host Response Test in Early Identification and Appropriate Intervention for Sepsis
Dr. Roy Davis provides an overview of the current challenges of sepsis diagnosis and management, specifically related to early identification and appropriate intervention. He describes how the host immune response can be leveraged by including a gene expression assay as part of the Sepsis Clinical Toolset. The proposed role for...
SeptiCyte® RAPID in Sepsis Cases with Malignancies or Treated with Anitneoplastics/Immunosuppressants
A study showing the performance of SeptiCyte RAPID in patients with malignancies and/or on anti-neoplastic or corticosteroid therapies. IMM-009-SCCM-04-01-SC
Immunexpress Presents Data Further Demonstrating SeptiCyte® RAPID Performance at the Society of Critical Care Medicine’s 50th Annual Critical Care Congress
Data Demonstrate the Performance of SeptiCyte® RAPID is Unaltered by Patient Malignancy or Treatment with Anti-neoplastics or Immunosuppressants Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced a research snapshot presentation of clinical data demonstrating the performance of SeptiCyte® RAPID in adult and pediatric...